FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

ROSELLINI MICHAEL 		2. Issuer Name and Ticker or Trading Symbol

NEXEON MEDSYSTEMS INC [ NXNN ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
_____ Officer (give title below)      __ X __ Other (specify below)
Shareholder holding over 5%
(Last)          (First)          (Middle)

1910 PACIFIC AVENUE, SUITE 20000 		3. Date of Earliest Transaction (MM/DD/YYYY)

6/23/2017
(Street)

DALLAS, TX 75201
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   6/23/2017     C (3) (4)    104890   A   (3) (4) 821890   D    
Common Stock   6/23/2017     C (3) (5)    102000   A   (3) (5) 702000   I   Michael Rosellini ROTH IRA   (1)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Warrants     (3) (4) 6/23/2017     J   (3) (4)       617000    12/2/2016   12/2/2019   Common Stock   104890     (3) (4) 0   D    
Warrants     (3) (5) 6/23/2017     J   (3) (5)       600000    12/2/2016   12/2/2019   Common Stock   102000     (3) (5) 0   I   Michael Rosellini ROTH IRA   (2)

Explanation of Responses:
(1)  Shares held by the Michael Rosellini ROTH IRA. Dr. Rosellini has the sole power to vote and dispose of the shares held by the Michael Rosellini ROTH IRA.
(2)  Warrants held by the Michael Rosellini ROTH IRA. Dr. Rosellini has the sole power to vote and dispose of the warrants/shares held by the Michael Rosellini ROTH IRA.
(3)  On March 21, 2017, the Company offered to current warrant holders who participated in the 2016 Private Placement which closed on December 2, 2016, the opportunity to convert their warrants into common stock of the Company on the following terms ("Warrant Conversion Offer"). The offer terms included the exercise of seventeen (17) warrants for seventeen (17) shares of the Company's common stock at an exercise price of $0.01 per share for every one hundred (100) warrants owned. The remaining eighty-three (83) warrants per hundred warrants owned would be cancelled. The offer was on an all-or-nothing basis to convert all warrants held by each warrant holder.
(4)  Pursuant to the terms of the Warrant Conversion Offer, on June 23, 2017, of the 617,000 warrants held by Dr. Rosellini individually, 104,890 warrants were converted into 104,890 shares of common stock, and 512,110 warrants were cancelled.
(5)  Pursuant to the terms of the Warrant Conversion Offer, on June 23, 2017, of the 600,000 warrants held by the Michael Rosellini ROTH IRA, 102,000 warrants were converted into 102,000 shares of common stock and 498,000 warrants were cancelled.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
ROSELLINI MICHAEL
1910 PACIFIC AVENUE, SUITE 20000
DALLAS, TX 75201


Shareholder holding over 5%

Signatures
/s/ Michael Rosellini 10/6/2017
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Nexeon Medsystems (CE) (USOTC:NXNN)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Nexeon Medsystems (CE) Charts.
Nexeon Medsystems (CE) (USOTC:NXNN)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Nexeon Medsystems (CE) Charts.